- Record quarterly revenues increase 14% to $31.9 million, exceeding the top end of guidance - GAAP EPS of $0.15, including the impact of a non-cash deferred tax asset adjustment that reduced earnings by $0.05 - Raising 2014 revenue guidance to a range of $125 million to $126 million, representing growth of 14% at new midpoint - Revising 2014 GAAP EPS guidance to a range of $0.65-$0.67, reflecting the Q3 non-cash tax adjustment and elevated legal expenses
Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of Vascular Solutions, Inc.
(“Vascular Solutions” or the “Company”) (NASDAQ:VASC) concerning
possible violations of federal securities laws.
The Rosen Law Firm announces that it is investigating potential
securities claims against Vascular Solutions, Inc. (NASDAQ:VASC)
resulting from allegations that the Company may have issued materially
misleading business information to the investing public.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.